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Seasonal epidemics caused by influenza A (H1 and H3 subtypes) and B viruses are a
major global health threat. The traditional, trivalent influenza vaccines have limited efficacy
because of rapid antigenic evolution of the circulating viruses. This antigenic variability
mediates viral escape from the host immune responses, necessitating annual vaccine
updates. Influenza vaccines elicit a protective antibody response, primarily targeting
the viral surface glycoprotein hemagglutinin (HA). However, the predominant humoral
response is against the hypervariable head domain of HA, thereby restricting the breadth
of protection. In contrast, the conserved, subdominant stem domain of HA is a potential
“universal” vaccine candidate. We designed an HA stem-fragment immunogen from the
1968 pandemic H3N2 strain (A/Hong Kong/1/68) guided by a comprehensive H3 HA
sequence conservation analysis. The biophysical properties of the designed immunogen
were further improved by C-terminal fusion of a trimerization motif, “isoleucine-zipper”,
or “foldon”. These immunogens elicited cross-reactive, antiviral antibodies and conferred
partial protection against a lethal, homologous HK68 virus challenge in vivo. Furthermore,
bacterial expression of these immunogens is economical and facilitates rapid scale-up.
Keywords: protein minimization, hemagglutinin stalk, subunit vaccine, pre-fusion conformation, antibody
response, Escherichia coli
Introduction
Influenza (flu) virus infection causes respiratory illness in humans. Preventive vaccination is
the best way of controlling influenza infections (1). Antiviral medications such as oseltamivir,
zanamivir, and peramivir are used to treat influenza infections (2, 3). Additionally, the application of
humanmonoclonal antibodies in therapeutic treatment of influenza infections is also being explored
(4–7).
The rapidly evolving influenza viruses are diverse and have been categorized into three immuno-
logical types: A, B, and C. The influenza A viruses are further classified on the basis of their surface
glycoproteins, hemagglutinin (HA) and neuraminidase (NA), into 18 HA and 11 NA subtypes
(8). H17 and H18 HAs are putative HA-like molecules, since their hemagglutination activity has
not been established. NA activity of N10 and N11 NAs has also not been shown. Antigenic
relatedness within HA facilitates clustering influenza A viruses into two major phylogenetic groups:
group 1 (subtypes: H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, and H18) and group 2
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(subtypes: H3, H4, H7, H10, H14, and H15) (8). Currently, only
influenza A (H1 and H3 subtypes) and B viruses cause seasonal
epidemics in humans (9). However, the perceived threat of highly
pathogenic avian influenza viruses (H5N1) and new reports of
influenza strains (H7N9, H6N1, and H10N8) crossing over the
species barrier and infecting humans (10–13) necessitate the
development of a “universal” influenza vaccine.
Currently, there are two variants of influenza vaccine: inacti-
vated influenza vaccine (IIV) and live attenuated influenza vac-
cine (LAIV). The efficacy of IIV and LAIV in children and
adults has been extensively evaluated (14, 15). All commercially
available influenza vaccines are manufactured by propagation of
virus in embryonated chicken eggs with a production time of
6–8months, except the trivalent recombinant influenza vaccine
[RIV3] (FluBlok, Protein Sciences) and cell culture-based IIV
[ccIIV3] (Flucelvax, Novartis)1. Therefore, manufacturing large
amounts of vaccine at short notice during an epidemic/pandemic
is difficult. Furthermore, preparedness against influenza infection
is compromised due to the lack of a foolproof method for the
annual selection of vaccine strains (16).
Hemagglutinin is highly immunogenic and its efficacy as a
stand-alone vaccine candidate has been extensively investigated
(1, 17). The precursor polypeptide (HA0) oligomerizes in the
endoplasmic reticulum (ER) and is transported to the cell surface
via the Golgi apparatus (18). HA0 is subsequently cleaved by
cellular proteases into the disulfide-linked, fusion competent HA1
and HA2 subunits (19). The immunodominant, membrane distal,
globular head domain of HA containing the receptor-binding site
(RBS) is assembled exclusively by the HA1 subunit, while the viral
membrane proximal, stem domain of HA is comprised primarily
of the HA2 subunit (20).
A comprehensive analysis of H3 HA sequences revealed a high
degree of conservation within the stem domain as opposed to
the variable head domain, in agreement with published results
(21, 22). The degree of conservation is inversely correlated with
antigenic distance between influenza strains. As shownpreviously,
the degree of overall residue conservation in HA within a subtype
is significantly greater than group-specific residue conservation
(1, 21), and therefore eliciting pan-influenza neutralizing antibod-
ies has remained elusive. The dominant antibody response post-
vaccination is against the variable head domain of HA, thereby
limiting vaccine efficacy. However, isolation of several broadly
neutralizing antibodies (bnAbs) targeting conserved epitopes in
the HA stem (4, 5, 23–27) has facilitated efforts in develop-
ing stem-based vaccine candidates with the potential to confer
hetero-subtypic protection (1). Nonetheless, it has been extremely
challenging to activate stem-directed bnAbs in humans because
of their low frequency in the influenza-specific memory B-cell
pool (21). The metastable conformation of the HA2 subunit in
the pre-fusion state of HA further compounds the difficulty in
exploiting the conserved epitopes of the HA stem in developing
a “universal” vaccine. Diverse strategies have been adopted to
express the HA stem in the pre-fusion conformation (28–32).
We have previously demonstrated the soluble expression of HA
stem-fragments in Escherichia coli (E. coli) by maintaining the
1http://www.cdc.gov/
interaction networkwithin theHA stem and introducing designed
mutations. These immunogens conferred robust subtype-specific
andmodest hetero-subtypic protection in vivo against influenza A
group 1 viruses (32).
Structural analysis of the HA stem reveals differences at the
N-terminus of the long alpha helix (LAH) and the composition
of ionizable residues proximal to the fusion peptide between
influenza A phylogenetic groups 1 and 2 (33). In order to mitigate
the threat of circulating influenza A viruses from these distinct
structural classes (H1 from group 1 and H3 from group 2), we
characterized anHA stem-fragment immunogen (H3HA10) from
the H3N2 strain (A/Hong Kong/1/68), which caused the “1968
influenza pandemic.” We evaluated the effect of trimerization
motifs, the coiled-coil isoleucine zipper (IZ) (34) and the globular,
β-rich “foldon” (35), belonging to disparate structural classes
as a C-terminal fusion to H3HA10. The oligomeric derivatives
of H3HA10 had improved biophysical properties and elicited
cross-reactive, antiviral antibodies inmice. The elicited antibodies
inhibited the entry of a heterologous H3 HA pseudotyped virus
in vitro. These immunogens conferred partial protection against
a lethal, homologous HK68 virus challenge in vivo. Additionally,
bacterial expression of these immunogens is cost-effective and
enables rapid production.
Materials and Methods
Sequence Analysis
All non-identical, full-length H3 HA protein sequences (3169
sequences) reported from human hosts were retrieved from the
NCBI-Flu Database2. These H3 HA sequences were subsequently
clustered at 99% homology using Cluster Database at High Iden-
tity with Tolerance (CD-HIT) (36) to filter-out 392 unique, rep-
resentative sequences, which were then multiply aligned using
CLUSTAL (37). The alignment file lists a quality score for every
position in the protein sequence, which is a measure of residue
conservation. The quality scores were then binned and mapped
onto the crystal structure of H3N2 A/Hong Kong/1/68 HA [pro-
tein data bank (PDB) ID: 1HGD (38)].
Protein Expression and Purification
The E. coli codon-optimized gene sequence of our designed con-
struct H3HA10 was synthesized with a stop codon at the 3’ end
(GenScript, USA). The gene was cloned into the expression vec-
tor pET-28a (+) (Novagen) in-frame with the N-terminal His-
tag between the NdeI and BamHI restriction sites. The E. coli
codon-optimized gene sequences encoding IZ and foldon were
individually synthesized (Abexome, India) with KpnI andHindIII
restriction sites at the 5’ and 3’ ends respectively. In order to
facilitate the cloning of a trimerization motif at the C-terminus of
H3HA10 to generate H3HA10-IZ and H3HA10-Foldon, the stop
codon in H3HA10 at the 3’ end was mutated and a unique KpnI
restriction site was generated using site-directed mutagenesis. All
the generated clones were confirmed by sequencing (Macrogen,
South Korea).
2http://www.ncbi.nlm.nih.gov/genomes/FLU/Database/nph-select.cgi?go=
database
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The designed proteins were expressed in E. coli BL21(DE3)
cells. H3HA10, H3HA10-IZ, and H3HA10-Foldon were all puri-
fied using a similar protocol from the soluble fraction of the
cell culture lysate. Briefly, a single transformed colony of E. coli
BL21(DE3) cells was inoculated into 50ml of Luria-Bertani broth
(HiMedia). The primary culture (50ml) was grown overnight
until saturation at 37°C. Subsequently, 2 L of Luria-Bertani broth
(500ml 4) was inoculated with 1% of the saturated primary
inoculum and grown at 37°C until an OD600 of ~0.6–0.8 was
reached. The cultures were then induced with 1mM isopropyl-β-
thiogalactopyranoside (IPTG). The cells were grown for another
12–16 h at 20°C post-induction. Next, the culture was spun down
at 5000 g for 15min at 4°C. The pelleted cells were resuspended
in 100ml of phosphate-buffered saline (PBS, pH 7.4). The cell
suspension was lysed by sonication and subsequently centrifuged
at 14,000 g for 45min at 4°C. The supernatant from the cell
culture lysate was incubated with buffer-equilibrated Ni-NTA
resin (GE HealthCare) for 2–3 h at 4°C to facilitate binding. The
protein was eluted in 2ml fractions using an imidazole gradient
(in PBS, pH 7.4). The eluted fractions were analyzed by SDS-
PAGE and pooled for dialysis against PBS (pH 7.4) containing
1mM EDTA. The dialyzed protein was concentrated to a final
concentration of ~5mg/ml and its identity was confirmed by
electrospray ionization-mass spectroscopy (ESI-MS).
Fluorescence Spectroscopy
The intrinsic fluorescence measurements for all proteins were
recorded at 25°C on a Jasco FP-6300 spectrofluorometer. The
protein samples (concentration of 1–3µM) were excited at a
wavelength of 280 nm, and emission was monitored between 300
and 400 nm. The spectrofluorometer slit widths for excitation and
emission were set at 3 and 5 nm, respectively. The represented
fluorescence signals were averaged over five consecutive scans
and corrected for buffer signals. The fluorescence signal of the
native protein was recorded in PBS (pH 7.4). The protein was
denatured in 7M guanidine hydrochloride (GdmCl) to record the
fluorescence signal in the unfolded state.
NMR Spectroscopy
One-dimensional 1HNMR spectra of all the protein samples were
recorded at 25°C on an Agilent 600MHz NMR spectrometer. The
spectra were recorded using a triple resonance cryo-probe fitted
with a z-axis only pulsed field gradient accessory. External DSS
was used for referencing 1H chemical shifts. A spectral width of
9615.4Hz was sampled. The excitation sculpting pulse scheme
was used to achieve solvent suppression (39). All the protein
samples were prepared in PBS (pH 7.4) (90% H2O:10% D2O). A
total of 1024 scans were recorded with a 1 s relaxation delay.
Gel Filtration Chromatography
The purified proteins were analyzed by gel filtration chromatog-
raphy on a Superdex-200 analytical gel filtration column (GE
HealthCare) equilibrated with PBS (pH 7.4) to determine their
oligomeric state under native conditions. The column was cal-
ibrated using a broad range of molecular weight markers as
indicated (GE HealthCare).
Antibody Binding Studies Using Surface
Plasmon Resonance
Binding affinity of the purified proteins (H3HA10, H3HA10-IZ,
and H3HA10-Foldon) and full-length recombinant HAs (rHAs)
(H3N2 A/Aichi/2/68 and H1N1 A/Puerto Rico/8/34) (Sino Bio-
logical Inc., Beijing, China) to the single-chain variable fragment
(scFv) of the stem-directed bnAbFI6v3was determined by surface
plasmon resonance (SPR) experiments performed with a Bia-
core2000 optical biosensor (Biacore, Uppsala, Sweden) at 25°C.
Recombinant FI6v3-scFv was produced as described previously
(32). Amine coupling chemistry was used to immobilize 750
response units (RU) of the ligand (FI6v3-scFv) to the surface of
a CM5 chip (GEHealthCare, Uppsala, Sweden). A sensor channel
immobilized with ovalbumin served as a negative-control for each
binding interaction. A concentration series of each analyte were
passed over the ligand(s) in a running buffer of PBS (pH 7.4)
with 0.05% P20 surfactant at a flow rate of 30µl/min to determine
the binding kinetics. The sensor surface was regenerated with 2M
MgCl2 after every binding event. The kinetic data was obtained
using the concentration of themonomer forH3HA10 and the con-
centration(s) of the trimer(s) for H3HA10-IZ, H3HA10-Foldon,
and rHAs. The concentration used for fitting the kinetic data was
in accordance with the oligomeric state of the protein as deter-
mined by gel filtration chromatography. The kinetic parameters
of binding were obtained by a global fitting of the data to the
simple 1:1 Langmuir interaction model using BIA EVALUATION
3.1 software.
Immunization and Virus Challenge Studies
The female BALB/c mice (4–5weeks old) (Taconic Farms, Inc.,
Germantown, NY, USA) used in this study were maintained at
the animal facilities of Merck Research Laboratories. The ani-
mal study was approved by the Merck Research Laboratories
Institutional Animal Care and Use Committee. Each group of
mice (n= 10) were immunized intramuscularly with 20µg of the
test immunogen along with 100µg CpG7909 adjuvant (TriLink
BioTechnologies, San Diego, CA, USA) at days 0 (prime) and
28 (boost). Naïve mice were used as controls. Serum samples
were obtained from all the mice 3weeks after prime and 2weeks
after boost by tail venipuncture and collected in Microtainer
serum separator tubes (BDBiosciences, Franklin Lakes, NJ, USA).
About 3weeks after the boost, mice were anesthetized with
ketamine/xylazine and challenged intranasally with 2LD90 (lethal
dose) of mouse-adapted H3N2 A/HK/1/68 virus in 20µL of PBS.
The mice were monitored for survival and weight change for
14 days post virus challenge.
Determination of Serum Antibody Titers
The serum antibody-titers against test immunogens (H3HA10,
H3HA10-IZ, and H3HA10-Foldon) were determined by ELISA.
Briefly, 200 ng of the protein was coated on 96-well Nunc plates
(Thermo Fisher Scientific, Rochester, NY, USA) and incubated
overnight at 4°C. Next, the plates were washed with PBS contain-
ing 0.05%Tween-20 (PBST) and blocked with 1% bovine serum
albumin (BSA) (Sigma) in PBST (PBSB) for 1 h. Antiserum raised
against the test immunogen was fourfold serially diluted in PBSB
and added to each well. The plates were washed with PBST after
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2 h of incubation with sera at room temperature. Fifty micro-
liters of alkaline phosphatase (ALP)-conjugated goat anti-mouse
secondary antibody (Sigma) used at a predetermined dilution
of 1:10000 in PBSB were added to each well and incubated at
room temperature for 2 h. After washing, the plates were devel-
oped using the chromogenic substrate p-nitrophenyl phosphate
(Sigma) and read at 405 nm (SPECTRAmax Plus 384, Molecular
Devices, USA). Antibody titer was determined as the reciprocal
of the highest serum dilution that gave an OD405 value above the
mean+ 2 SD of control wells.
Binding of Antisera to Full-Length Recombinant
HAs
The binding of antibodies elicited by the test immunogens
to a panel of full-length rHA proteins was determined by
ELISA. Briefly, 200 ng of mammalian-cell expressed rHA pro-
teins (H3N2 A/Aichi/2/68, H3N2 A/Brisbane/10/07, H7N7
A/chicken/Netherlands/1/03, H1N1 A/Puerto Rico/8/34, and
H1N1 A/California/04/2009 from Sino Biological Inc., Beijing,
China) were coated on 96-well Nunc plates (Thermo Fisher Sci-
entific, Rochester, NY, USA) and incubated overnight at 4°C.
Ovalbumin (200 ng/well) coated wells were used as a control
for non-specific binding. Plates were washed with PBST and
subsequently blocked with PBSB. The rHA proteins were then
incubated for 2 h with a fourfold serial dilution of the antisera
(starting at a dilution of 1:100). The plates were then washed
with PBST and incubated for 2 h at room temperature with ALP-
conjugated goat anti-mouse secondary antibody (Sigma) used at
a dilution of 1:10000. After another round of washing, the plates
were developed with the chromogenic substrate p-nitrophenyl
phosphate (Sigma). The antibody titer against rHA proteins was
determined as the reciprocal of the highest serum dilution that
gave anOD405 (SPECTRAmax Plus 384,Molecular Devices, USA)
value above the mean+ 2 SD of control wells.
Pseudotyped Virus Particle Entry Inhibition Assay
The antisera raised against the designed immunogens were
tested in a pseudotype virus particle entry inhibition assay
as described previously (40, 41). Briefly, HIV gag-pol plasmid
p8.91, firefly luciferase expressing plasmid pCSFLW, H3 HA
(A/Wisconsin/67/2005) expressing plasmid, NA expressing plas-
mid (A/Udorn/307/1972N2), and pCAGGS-HAT (42) expressing
plasmid were co-transfected into human embryonic kidney (HEK
293T/17) cells using Fugene-6 transfection reagent (Promega)
and incubated for 24 h. The supernatant containing the released
pseudotypes was harvested 48 h post-infection, filtered through a
0.45µm filter, and stored at 80°C until further use.
Serial dilutions of the antisera were incubated with 2 107
relative luminescence units (RLUs) of pseudotypes/well in 96-
well flat-bottomed white plates (Nunc) in a final volume of 50µl
at 37°C for 1 h. After the incubation, 1.5 104 HEK293T cells
were added to each well. The plates were subsequently incu-
bated for another 48 h at 37°C. The luminescence signals were
assayed using the Bright-Glo assay system (Promega). The half-
maximal inhibitory concentrations (IC50) of entry inhibition were
determined using Prism v6.0 (GraphPad Software).
Statistical Analysis
The differences in antibody/entry inhibition titers were analyzed
by analysis of variance and Student’s t-test. The fractional body
weight of mice was calculated relative to their initial body weight.
Differences in the mean fractional body weight of surviving mice
were analyzed using analysis of variance and Student’s t-test.
Kaplan–Meier survival analysis with the log rank significance test
was used to analyze the difference in survival across groups.
Results
Design of HA Stem-Fragment Immunogens
Current influenza vaccines elicit a robust strain-specific antibody
response which neutralizes the virus and confers protection (1).
The primary response is against the immunodominant antigenic
sites in the head domain of HA (43). However, the virus has
evolved amechanism of “antigenic drift” whereinmutations accu-
mulated in these antigenic sites facilitate escape from the host
immune pressure. Immune selection pressures coerce influenza
virus into presenting a continually “moving target”. Therefore, we
analyzed a large dataset of full-length H3 HA sequences (3169
sequences) reported from human hosts to identify conserved
regions on HA. In agreement with previous results (1, 21, 22),
the HA stem is on average more conserved than the variable
head domain within a subtype (Figure 1A). However, there are
pockets of high conservation even within the head domain of HA
and monoclonal antibodies binding within the RBS have been
isolated that neutralize drift variants of a HA subtype (6). The
conservation within the HA stem has been ascribed to the less-
than-optimal accessibility on the virion surface and the functional
restraint imposed by conformational changes in the stem domain
that are essential for infection. However, recent cryoEM studies
of H1N1 A/California/7/2009 virus pre-incubated with the stem-
directed bnAb C179 demonstrated that ~75% of HA trimers on
the virion surface were in complex with the antibody (44). The
study demonstrated that antibody binding to the HA stem on the
virion is not severely impeded by accessibility.
A large fraction (90%) of the epitopes identified by the human
B-cell population is conformation sensitive (45). In fact, extensive
conformational rearrangement of the HA stem at low pH disrupts
the epitope of HA stem-directed bnAbs. We analyzed the interac-
tion network within H3 HA [H3N2 A/Hong Kong/1/68, PDB ID:
1HGD (38)] using PREDBURASA, as described previously (46),
to identify HA stem fragments defined by stable structural break-
points. During HA protein minimization, we performed iterative
calculations to identify residue fragments: 191-461, 2901-3211,
and 442-1132 (included in H3HA10) within the stem domain
having minimalistic interactions with the rest of HA (Figure 1B).
Residues from HA1 and HA2 subunits are distinguished by sub-
scripts 1 or 2 respectively. The termini of HA stem-fragments in
H3HA10 also had optimal Cα-Cα distances for “molecular stitch-
ing” as indicated in Figure 1B from our analysis of the Cα-Cα
distance matrix of H3 HA. These fragments were connected with
flexible, soluble linkers as described previously (47). The loss of
native contacts inH3HA10 as a consequence of proteinminimiza-
tion exposes previously buried hydrophobic patches which can
potentially aggregate. We re-surfaced these hydrophobic patches
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FIGURE 1 | HA sequence conservation guided immunogen design.
(A) The residue conservation among H3 HA human isolates is mapped onto a
surface representation of H3N2 A/Hong Kong/1/68 HA trimer [PDB ID: 1HGD
(38)]. The quality score (Q-score) at every position in the protein sequence,
which is a measure of residue conservation, was obtained from a multiple
sequence alignment of H3 HA sequences (n= 3169) and binned. The HA stem
is well conserved within a subtype. One monomer is colored according to the
Q-score scale. Rest of HA (gray). (B) Conserved HA stem-fragments are
“stitched” together in H3HA10 (cartoon). One monomer is colored according to
the Q-score scale [indicated in (A)] to highlight the residue conservation in the
designed immunogen. Stable structural breakpoints with optimal Cα–Cα
distances (shown in another monomer) were determined by analysis of the H3
HA distance matrix. Soluble, flexible linker as indicated (black, dashed curve)
was used to connect the HA1-subunit fragment 191-461 (pale yellow) to
2901-3211 (brown). A 6-residue linker (GSAGSA) connects the HA1 (brown) and
HA2 (magenta) subunits in H3HA10. The third monomer is in gray.
(C) Derivative(s) of H3HA10 were made with C-terminal trimerization motif(s), IZ,
and foldon (34, 35). The figures (A,B) were rendered using PyMOL.
with polar amino acid substitutions as described previously (32).
Wehave previously designed stable influenza andHIV-1 immuno-
gens using a similar approach (28, 30, 32, 48). The followingmuta-
tions were introduced in H3HA10 to resurface the hydrophobic
patches: V201S, V2971T, I3001R, Y3021S, M3201Q, and I452T. In
the full-length H3 HA, Cys2811 and Cys3051 form an intramolec-
ular disulfide bond. Since residueCys2811 was not incorporated in
H3HA10, we mutated Cys3051 to Ser to prevent the formation of
incorrect, intermolecular disulfide bonds in the absence of its cog-
nate partner (Cys2811). Aspartate mutations (F632D and V732D),
previously shown to destabilize the low-pH conformation of HA
(28) were also incorporated in H3HA10. We have previously
shown that synthetic trimerization motifs promote the oligomer-
ization of HA stem in the absence of the trans-membrane (TM)
domain (32). We made derivatives of H3HA10 with the coiled-
coil IZ (H3HA10-IZ) and the globular, β-rich “foldon” (H3HA10-
Foldon) (Figure 1C). Figure S1 in SupplementaryMaterial lists the
sequences of all the designed constructs.
Protein Purification and Characterization
Recombinant protein expression in prokaryotic systems is eco-
nomical and amenable for rapid production. However, prokary-
otic expression of heterologous viral proteins in native-like con-
formation has been challenging.Human pathogenic viruses hijack
the host protein machinery for synthesis and undergo post-
translational modifications (PTMs). Influenza proteins expressed
in E. coli lack PTMs and can potentially aggregate. Previous efforts
at bacterial expression of HA resulted in inclusion bodies and
entailed refolding (28, 30, 49). However, in this study, all of our
designed immunogens were purified from the soluble fraction
of the E. coli cell culture lysate. We obtained modest protein
yields of ~10-15mg/l of the culture, using unoptimized shake-
flask cultures. We could achieve 95% purity as assayed by SDS-
PAGE using a single affinity-purification step (Figure 2A). We
did not observe any higher order impurities. The purity of the
protein was also confirmed using ESI-MS over a mass range of
10–200 kDa.
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FIGURE 2 | Protein purification and biophysical characterization of HA stem-fragment immunogens.
(Continued)
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FIGURE 2 | Continued
(A) SDS-PAGE profile of the purified proteins. Lane 1: PageRuler Plus
prestained protein ladder (Thermo Scientific), lane 2: H3HA10, lane 3:
H3HA10-IZ, and lane 4: H3HA10-Foldon. All the designed proteins were
purified from the soluble fraction of E. coli cell culture lysate. H3HA10 was
partially degraded upon purification. A C-terminal cleavage of 1367.4Da
(determined by mass spectrometry) was observed
(H3HA10∆Ct= 16335.9Da). The derivative(s) of H3HA10 with C-terminal
trimerization motif(s) were resistant to in situ protein degradation. The
migration of the purified proteins in a SDS-PAGE is marginally retarded. The
SDS-PAGE gel was stained with Coomassie. (B) Fluorescence emission
spectra of HA stem-fragment immunogens were recorded under native
(PBS, pH 7.4) or denaturing conditions (7M GdmCl in PBS, pH 7.4) as
indicated. Unlike H3HA10, both H3HA10-IZ and H3HA10-Foldon showed a
significant red-shift in the emission maxima upon denaturation indicating a
compact tertiary conformation. (C) 1D 1H NMR spectra of HA
stem-fragment immunogens. The improved chemical shift dispersion in the
upfield (0.5–1.0 ppm) and/or downfield (9–11 ppm) regions of the 1H NMR
spectra of H3HA10-IZ and H3HA10-Foldon is consistent with the
fluorescence data, indicating that trimerization motifs assist in the folding of
the HA stem in the absence of the transmembrane (TM) domain, with
H3HA10-Foldon appearing more structured than H3HA10-IZ.
Surprisingly, partial degradation of H3HA10 was observed
upon purification. The addition of protease inhibitor cock-
tail tablet (cOmplete ULTRA Tablets, Roche) during purifica-
tion did not prevent this. A C-terminal cleavage of 1367.4Da
(H3HA10∆Ct= 16335.9Da) was confirmed by mass spectrom-
etry. It has been previously shown that cellular proteases can
degrade protein segments with extended conformations in situ
(50). We hypothesized that C-terminal conjugation of H3HA10
with a synthetic trimerization motif might abate in situ protein
degradation. Encouragingly, we observed that the addition of
either IZ or foldon domains could completely curtail protein
degradation in situ (Figure 2A).
The integrity of the protein hydrophobic core was probed by
intrinsic fluorescence measurements. H3HA10 did not exhibit
red-shift in the emission maximum upon denaturation with
GdmCl, indicating an extended conformation which may explain
the observed in situ protein degradation. In contrast, both
H3HA10-IZ and H3HA10-Foldon showed significant red-shift in
the emission maxima upon denaturation, indicating a compact
tertiary conformation (Figure 2B). These results were further
substantiated by the one-dimensional 1H-NMR spectrum of the
designed immunogens. TheC-terminal trimerizationmotifs assist
the folding of H3HA10. Both H3HA10-IZ and H3HA10-Foldon
have improved solution properties as inferred from resolved
resonance lines in the upfield (0.5–1.0 ppm) and/or downfield
(9–11 ppm) regions of the 1H-NMR spectrum (Figure 2C). The
upfield shifted signals result from interactions between methyl
protons that are spatially close to buried aromatic rings in the
hydrophobic core.
The core of HA stem is assembled by three long, α-helical,
parallel coiled-coils. The recapitulation of native HA contacts
would promote the trimerization of HA stemmimetics. We deter-
mined the oligomeric state of the designed HA stem-fragment
proteins using gel-filtration chromatography. The extended con-
formation of H3HA10 (inferred from fluorescence and 1H-NMR
measurements) impedes accurate molecular weight estimation
from size exclusion chromatography because of disproportionate
retention along the column. However, the protein probably elutes
as a monomer. The shoulder of the elution peak corresponds
to H3HA10∆Ct. In contrast, H3HA10-IZ and H3HA10-Foldon
predominantly elute as a homogenous oligomer (probably trimer)
and do not form higher order aggregates (Figures 3A,B). This
is consistent with previous reports which showed that trimer-
ization motifs facilitate the oligomerization of ∆TM (transmem-
brane domain deleted) HA stem (32). The molecular weight
(~72.5 kDa) of the oligomer estimated from gel-filtration is
FIGURE 3 | Oligomeric state of “headless” HA stem immunogens. (A)
Size-exclusion chromatography of the purified proteins was done at room
temperature under non-denaturing conditions using a buffer (PBS, pH 7.4)
equilibrated analytical Superdex-200 column. The disproportionate retention
of H3HA10 because of an extended conformation (inferred from fluorescence
and 1D 1H-NMR measurements) impedes accurate molecular weight
estimation. The shoulder of the elution peak corresponds to H3HA10∆Ct.
H3HA10-IZ and H3HA10-Foldon predominantly elute as a homogenous
oligomer (probably trimer) and do not form higher order aggregates. (B) The
column was calibrated using a broad range of molecular weight markers (x).
The elution volume(s) of the designed protein(s) corresponding to A220 signal
maxima were plotted [open circles ()] on the calibration curve to estimate the
molecular weights.
marginally higher, but close to the theoretical molecular weight
of a trimer (21.5 3= 64.5 kDa). The discrepancy in the
aforementionedmolecular weight estimates of the oligomer arises
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TABLE 1 | HA stem-fragment immunogens bind conformation specific
bnAb.
Analyte FI6v3-scFva
kon (M–1s–1) koff (s–1) KD (nM)
H3HA10 8.11103 3.4110–3 412.411.6
H3HA10-IZ 1.01104 9.0310–4 89.53.2
H3HA10-Foldon 9.27103 1.0610–3 114.36.8
H3 A/Aichi/2/68 rHA 2.29104 5.0710–4 22.12.3
H1 A/Puerto Rico/8/34 rHA 1.93105 2.2210–3 11.51.3
a750 RU of FI6v3-scFv was immobilized on the surface of a CM5-chip.
The kinetic parameters for binding were determined by surface plasmon resonance (SPR).
possibly because the designed HA stem-fragment proteins are not
globular.
The pan-influenza neutralizing antibody FI6 is selective in
binding exclusively the pre-fusion conformation of HA. FI6 binds
a conformation sensitive epitope in the HA stem that is dis-
rupted by the structural re-arrangement of HA in the post-
fusion conformation (25). Therefore, binding of the designed
“headless” stem immunogens to FI6 is an infallible quality con-
trol of their conformation. The HA stem-fragment immuno-
gen H3HA10 bound FI6v3-scFv with sub-micromolar affinity
(412.4 11.6 nM) (Table 1; Figure S2 in SupplementaryMaterial).
On the other hand, full-length rHA (H3 A/Aichi/2/68) bound
FI6v3-scFv with very high affinity (22.1 2.3 nM). There are
several factors that could contribute to the weaker binding of
H3HA10 to FI6v3-scFv. Primarily, the designed stem immuno-
gen includes only a subset (~47%) of the FI6 epitope. Next, the
aggregation state of H3HA10 in solution (monomer) could con-
tribute to the slower kon and higher koff in comparison to the
trimeric, full-length rHA (Table 1; Figures S2 in Supplementary
Material). Accordingly, the oligomeric derivatives of H3HA10
had considerably tighter binding to FI6v3-scFv. H3HA10-IZ and
H3HA10-Foldon had an equilibrium dissociation constant (KD)
of 89.5 3.2 and 114.3 6.8 nM, respectively (Table 1; Figures
S2 in Supplementary Material).
Characterization of Antigen-Specific Antibody
Response
All the designed HA stem-fragment proteins were highly
immunogenic inmice and elicited a robust antibody responsewith
self-titers1 106. The antibody titers against the conserved HA
stem following a primary infection is lower than the titers elicited
against the immunodominant, variable head domain. The pre-
dominant antibody response post-infection/vaccination is against
the canonical antigenic sites in the globular head domain of HA
(1). We assayed antibody binding to full-length rHAs to deter-
mine the breadth of antigen (Ag) elicited response. The homol-
ogous anti-HA titer was determined using H3N2 A/Aichi/2/68
HA that is nearly identical (99.6%) to H3N2 A/HK/1/68 HA.
The anti-HK68 convalescent sera had a homologous anti-HA titer
of ~2.5 104, but extremely low/undetectable heterologous anti-
HA titers suggesting a head-specific response. In contrast, the
oligomeric stem-fragment immunogens elicited modest titers of
cross-reactive, anti-HA antibodies, validating our design rationale
(Figures 4A–C).We achieved a higher cross-reactive anti-HA titer
by focusing the antibody response to the HA stem through suc-
cessful engineering of the conserved HA stem-fragments (Table
S1 in Supplementary Material).
The structural divergence in HA stem between influenza
groups 1 and 2 establishes distinct group-specific antibody bind-
ing profiles. The HA stem directed bnAbs CR6261, F10, and
C179 neutralize influenza A group 1 viruses exclusively (4, 24,
44). Binding of these bnAbs to group 2 HAs is abolished because
of an N-linked glycan at residue N381 (HA1 subunit), which is
highly conserved (6). The glycan shields the conserved eptiope
on the HA stem, thereby abrogating the neutralization activity
of these bnAbs against influenza A group 2 viruses. A “univer-
sal” influenza vaccine must breach this group-restricted antibody
response. Extensive screening of over 13,000monoclonal antibod-
ies (over 90% were influenza-specific) from an individual donor
led to isolation of the bnAb FI6 whose epitope overlaps with that
of group 1 specific stem-directed bnAbs (25). Binding of the bnAb
FI6 to H3HA is enabled by reorientation of the N-linked glycan at
residueN381 upon antibody approach (25). The proteins designed
in this study were purified from E. coli, and hence lack PTMs
like N-linked glycosylation. We therefore hypothesized that non-
glycosylated HA stem immunogens mimicking the native, pre-
fusion conformation ofHAcould elicit antibodieswhich bindHAs
belonging to both groups 1 and 2. Encouragingly, sera elicited by
H3HA10-IZ and H3HA10-Foldon had detectable antibody titers
against divergent H1 HAs belonging to group 1 (Figures 4D,E).
The stem-directed neutralizing antibodies interfere with the
establishment of viral infection by inhibiting membrane fusion.
These antibodies do not prevent virus attachment to host cell
receptors detected in a hemagglutinin inhibition (HI) assay (51).
We measured the serum neutralization titers using a pseudo-
typed virus particle entry inhibition assay (40). The sera elicited
by HA stem-fragment immunogens showed significant entry
inhibition of the heterologous H3 A/Wisconsin/67/2005 (with
A/Udorn/307/1972 N2) influenza pseudotyped virus (Table 2),
above the background of the naïve sera (Figure S3 in Supplemen-
tary Material). The reason(s) for the high background with the
naïve mice sera are not well understood.
HA Stem-Fragment Immunogens Confer Partial
Protection In vivo
We evaluated the in vivo efficacy of HA stem-fragment
immunogens against lethal viral infection. Mice were challenged
intranasally with a lethal dose (2LD90) of homologous mouse-
adapted H3N2 A/HK/1/68 virus 3weeks after the secondary
immunization (boost). H3HA10 conferred minimal protection
(20%) against virus challenge. Although, the oligomeric
derivatives ofH3HA10 elicited cross-reactive, anti-HA antibodies,
they conferred only partial protection (40–50%) (Figure 5A).
However, all surviving mice showed significant weight recovery
by the end of the study period after initial weight loss (Figure 5B).
Discussion
The emergence of “novel” influenza virus strains with the poten-
tial to cross-over the species barrier and infect humans has raised
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FIGURE 4 | The designed immunogens elicit broadly cross-reactive,
anti-HA antibodies in mice. The antigen-specific antibody response of
the pooled sera (n= 10 mice/group, collected 2weeks after boost) was
evaluated in an ELISA with full-length rHA proteins: (A) H3N2 A/Aichi/2/68,
(B) H3N2 A/Brisbane/10/07, (C) H7N7 A/chicken/Netherlands/1/03,
(D) H1N1 A/Puerto Rico/8/34, and (E) H1N1 A/California/04/2009. The
oligomeric derivatives of H3HA10 induced a higher cross-reactive anti-HA
antibody response in comparison to mice that received a sub-lethal,
protective dose (0.1LD90) of mouse-adapted HK68-virus (convalescent
sera).
TABLE 2 | In vitro pseudotyped virus particle entry inhibition with HA stem
immunized mice sera.
Immunogen IC50a
H3HA10 13479
H3HA10-IZ 9082
H3HA10-Foldon 16935
Naïve 8287
a IC50 titer is the reciprocal of the sera dilution at which half-maximal entry inhibition was
observed. Sera were collected 14days after the boost and pooled.
The antibodies elicited by HA stem-fragment immunogens inhibited the entry of a het-
erologous H3 A/Wisconsin/67/2005 (with A/Udorn/307/1972 N2) influenza pseudotype
virus.
alarms across the global health surveillance system. The limita-
tions of current vaccines, namely, strain-specific protection and
lengthy production time, have necessitated the development of
novel vaccines (1).
A primary influenza infection/vaccination results in an anti-
body response biased toward the immunodominant, hyper-
variable antigenic sites in the globular head domain of HA (43).
Alternative vaccination strategies have been adopted to skew the
humoral response in favor of the conserved HA stem which can
potentially increase the breadth of protection. A vaccination regi-
men with repeated DNA and/or protein immunizations with full-
length, chimeric HAs was shown to enhance the stem-directed
antibody response (52). Full-length HA displayed on ferritin-
nanoparticles elicited stem-directed antibodies in addition to a
robust head-directed response (53). HA N-linked glycosylation
has also been engineered to induce cross-strain protection against
influenza infection (54, 55).
In alternate approaches, the HA stem has been stabilized
in the absence of the globular head domain. We have previ-
ously demonstrated that site-specific charged (Asp) mutations
can destabilize the post-fusion conformation of the HA stem and
shift the equilibrium toward the metastable, pre-fusion confor-
mation at neutral-pH (28). The bacterially expressed HA stem
conferred complete protection against virus challenge in mice.
However, these proteins formed inclusion body aggregates upon
expression and required refolding. The refolded proteins were
aggregation prone. In subsequent studies, we engineered HA
stem sub-structures to elicit a stem-specific immune response
(32, 56). We successfully designed “headless” HA stem-fragment
immunogens from influenza A group 1 viruses which were puri-
fied from the soluble fraction in E. coli. These thermotolerant,
trimeric immunogens conferred robust subtype-specific protec-
tion in vivo (32).
Structural divergence in the stem-domain of HA between
groups 1 and 2 results in the group-specific neutralization pro-
file of various stem-directed bnAbs (6). In lieu of a “univer-
sal” influenza vaccine, a composite of immunogen(s) from both
groups is a practical alternative. Herein, we report the charac-
terization of HA stem-fragment immunogens designed from the
H3N2 strain (A/HongKong/1/68) that caused the “1968 influenza
pandemic”.
We intended to enhance the breadth of Ag-specific immune
response by targeting the conserved regions of HA. An exhaustive
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FIGURE 5 | In vivo efficacy of HA stem-fragment immunogens
against lethal homologous virus challenge. Mice (n= 10/group) were
vaccinated with the test immunogens on days 0 (prime) and 28 (boost). The
immunized mice were challenged 3weeks after boost with 2LD90 of
mouse-adapted HK68 virus. (A) Survival and (B) average weight changes
(of surviving mice) were monitored for 14 days post virus challenge. Naïve
mice were used as controls. The oligomeric derivatives of H3HA10
conferred partial protection (40–50%). However, all the surviving mice
showed significant weight recovery by end of the study period after initial
weight loss. The efficacy of test immunogens was evaluated by analyzing
the Kaplan–Meier survival curves with log rank significance test (p-values:
***0.005, **0.05, and n.s.0.05). The difference(s) in fractional body
weight(s) after recovery (at day 14) and maximal loss (day 9) were analyzed
by Student’s t-test (p-value: **0.05).
analysis of full-length H3 HA sequences revealed multiple
sub-structures within the HA stem that are conserved. These
conserved sub-structures form discrete epitopes that are targeted
by different bnAbs: the pan-influenza bnAb FI6 binds the epitope
lined by residues of the A-helix (HA2-subunit) (25), while the
viral membrane proximal β-sheet lines the epitope of group 2
specific bnAbs CR8020 and CR8043 (5, 27). Although, cryo-EM
studies demonstrated that HA trimers on the virion surface could
complex with a stem-directed bnAb (44), the relative accessi-
bility of HA stem sub-structures on the crowded virion surface
may influence the in vivo efficacy of vaccine candidates target-
ing these epitopes separately. The designed HA stem-fragment
immunogen, H3HA10, comprises a subset (~47%) of the bnAb
FI6 epitope and completely lacks the epitopes for CR8020 and
CR8043. The interaction network of the HA stem was minimally
perturbed to mimic the native, pre-fusion conformation in the
designed immunogen. Further, the C-terminal conjugation of
H3HA10 with a trimerization motif (IZ/foldon) improved the
solution properties of the protein. Soluble prokaryotic (E. coli)
expression of the designed immunogens enables rapid production.
Although the oligomeric derivatives of H3HA10 elicited cross-
reactive anti-HA antibodies that inhibited entry of a heterologous
H3 HA pseudotyped virus in vitro, they conferred only partial
protection (40–50%) after virus challenge in mice. There is dis-
connect between the high entry inhibition IC50 values (Table 2)
and the lack of a robust protective response (Figure 5A) elicited
by the designed immunogens. The high entry inhibition IC50
values are likely to be the consequence of using a highly sen-
sitive entry inhibition assay. The lack of a strong correlation
between the entry inhibition IC50 values and survival warrants
further investigation into the role of antibody-dependent effector
functions such as antibody-dependent cell-mediated cytotoxicity
(ADCC) and other Ag-specific antiviral mechanism(s). There is
considerable scope to improve our current design to enhance the
in vivo efficacy, for instance, by incorporating a larger footprint of
the bnAb FI6 epitope.
Although the H3HA10 series of immunogens described here
are expressed in soluble form and are not aggregation prone,
they had relatively lower in vivo efficacy as compared to our
previously designedHA stem immunogen (H3HA6). This is prob-
ably because H3HA6 includes the entire HA stem presenting
distinct epitopes of multiple bnAbs to the immune system (28).
The oligomeric derivatives of the designed HA stem immunogens
elicited a robust antibody response against the homologous H3N2
HA. While these antibodies were cross-reactive, the titers against
heterologous H3 and H7 HAs were 10-fold lower. The elicited
antibodies also exhibited weak cross-group (group 1 HAs) reac-
tivity. The antibody-HA reactivity profile correlates well with the
residue conservation between the influenza strains evaluated in
our assay (Table S1 in Supplementary Material). Therefore, we
hypothesize that increasing the footprint of bnAb epitopes in the
designed immunogen can further improve the binding profile. A
comparison with the designed HA stem-fragment immunogen,
H1HA10 (32), from influenza A group 1 viruses reaffirms the
necessity to include a larger footprint of bnAb epitopes. H1HA10
includes ~70% of the pan-influenza neutralizing bnAb F16 epi-
tope, while H3HA10 includes only ~47% of the epitope. Fur-
ther design optimization will explore mutations to increase the
strength of inter-protomer interactions. For example, a recent
study demonstrated that engineered Cys mutations in the LAH
of the HA2-subunit of pandemic HA (H1N1 A/California/2009)
promote the formation of covalent trimers (31). Despite these
lacunae, the immunogens described in this study do provide
partial protection against lethal pathogenic challenge and elicit
broadly cross-reactive HA stem-directed antibodies. Our studies
provide a framework for the design of future influenza A group 2
HA stem-fragment immunogens.
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